{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T05:16:05Z","timestamp":1755839765532,"version":"3.40.5"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,20]]},"abstract":"<jats:p>Hepatocellular carcinoma is the predominant form of primary liver cancer and is the leading cause of cancer-related death. The aim of this study was to construct a nomogram to predict cancer-specific survival (CSS) in middle-aged patients with advanced hepatocellular carcinoma. Clinical data were downloaded from the Surveillance, Epidemiology and End Results (SEER) database for middle-aged patients diagnosed with advanced hepatocellular carcinoma (AJCC stage III and IV) from 2000 to 2019. The patients were randomized in a 7:3 ratio into training cohort and validation cohort. Univariate and multivariate Cox regression analyses were performed in the training cohort to screen for independent risk factors associated with cancer-specific survival for the construction of nomogram. The nomogram was examined and evaluated using the consistency index (C-index), area under the curve (AUC), and calibration plots. The clinical application value of the model was evaluated using decision curve analysis (DCA). A total of 3026 patients were selected, including 2244 in the training cohort and 962 in the validation cohort. Multivariate analysis revealed gender, marital status, American Joint Committee on Cancer (AJCC) stage, tumor size, bone metastasis, lung metastasis, alpha-fetoprotein (AFP) level, surgery, radiotherapy, chemotherapy as independent risk factors, which were all included in the construction of the nomogram. In the training cohort, the AUC values were 0.74 (95% CI: 0.76\u20130.72), 0.78 (95% CI: 0.82\u20130.75), and 0.82 (95% CI: 0.86\u20130.78) at 1-, 3-, and 5-year CSS, respectively. The calibration plots showed good consistency between the actual and predicted values. The DCA curves indicated that the nomogram model could more accurately predict CSS at 1-, 3-, and 5-year in middle-aged patients with advanced hepatocellular carcinoma compared with the AJCC staging system. Highly similar results to the training cohort were also observed in the validation cohort. In the risk stratification system, good differentiation was shown between the 2 groups, and Kaplan\u2013Meier survival analysis indicated that surgery could prolong patient survival. In this study, we developed a nomogram and risk stratification system for predicting CSS in middle-aged patients with advanced hepatocellular carcinoma. The prediction model has good predictive performance and can help clinicians in judging prognosis and clinical decision making.<\/jats:p>","DOI":"10.1097\/md.0000000000039480","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T16:03:14Z","timestamp":1727107394000},"page":"e39480","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Construction and validation of a nomogram for predicting cancer-specific survival in middle-aged patients with advanced hepatocellular carcinoma: A SEER-based study"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0277-2664","authenticated-orcid":false,"given":"Ziqiang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Hubei Provincial Clinical Medicine Research Center for Minimally Invasive Diagnosis and Treatment of Hepatobiliary and Pancreatic Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China"},{"name":"Department of General Surgery, Tongji Hospital, Tongji University School of Medicine, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyong","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Hubei Provincial Clinical Medicine Research Center for Minimally Invasive Diagnosis and Treatment of Hepatobiliary and Pancreatic Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhidong","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Hubei Provincial Clinical Medicine Research Center for Minimally Invasive Diagnosis and Treatment of Hepatobiliary and Pancreatic Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Hubei Provincial Clinical Medicine Research Center for Minimally Invasive Diagnosis and Treatment of Hepatobiliary and Pancreatic Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengpeng","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Hubei Provincial Clinical Medicine Research Center for Minimally Invasive Diagnosis and Treatment of Hepatobiliary and Pancreatic Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Hubei Provincial Clinical Medicine Research Center for Minimally Invasive Diagnosis and Treatment of Hepatobiliary and Pancreatic Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5469-6240","authenticated-orcid":false,"given":"Kun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Hubei Provincial Clinical Medicine Research Center for Minimally Invasive Diagnosis and Treatment of Hepatobiliary and Pancreatic Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/nm.4438","article-title":"Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.","volume":"23","author":"Broutier","year":"2017","journal-title":"Nat Med"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.","volume":"132","author":"El-Serag","year":"2007","journal-title":"Gastroenterology"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg iv238, 2018).","volume":"29","author":"Vogel","year":"2019","journal-title":"Ann Oncol"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"848716","DOI":"10.3389\/fpubh.2022.848716","article-title":"Development and validation of a nomogram to predict cancer-specific survival for middle-aged patients with early-stage hepatocellular carcinoma.","volume":"10","author":"Wen","year":"2022","journal-title":"Front Public Health"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma.","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects.","volume":"5","author":"Tang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.2007.12.9791","article-title":"How to build and interpret a nomogram for cancer prognosis.","volume":"26","author":"Iasonos","year":"2008","journal-title":"J Clin Oncol"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S1470-2045(14)71116-7","article-title":"Nomograms in oncology: more than meets the eye.","volume":"16","author":"Balachandran","year":"2015","journal-title":"Lancet Oncol"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/cid\/ciaa443","article-title":"A tool for early prediction of severe coronavirus disease 2019 (COVID-19): a multicenter study using the risk nomogram in Wuhan and Guangdong, China.","volume":"71","author":"Gong","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/neuonc\/noz191","article-title":"An independently validated survival nomogram for lower-grade glioma.","volume":"22","author":"Gittleman","year":"2020","journal-title":"Neuro Oncol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"106267","DOI":"10.1016\/j.ijsu.2022.106267","article-title":"A nomogram for decision-making assistance on surgical treatment of chronic osteomyelitis in long bones: establishment and validation based on a retrospective multicenter cohort.","volume":"99","author":"Zhu","year":"2022","journal-title":"Int J Surg"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/cam4.3613","article-title":"A practical nomogram and risk stratification system predicting the cancer-specific survival for patients with early hepatocellular carcinoma.","volume":"10","author":"Yan","year":"2021","journal-title":"Cancer Med"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"21376","DOI":"10.1038\/s41598-020-78545-2","article-title":"Construction and validation of a nomogram for predicting cancer-specific survival in hepatocellular carcinoma patients.","volume":"10","author":"Liu","year":"2020","journal-title":"Sci Rep"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"e204930","DOI":"10.1001\/jamaoncol.2020.4930","article-title":"Systemic therapy and sequencing options in advanced hepatocellular carcinoma a systematic review and network meta-analysis.","volume":"6","author":"Sonbol","year":"2020","journal-title":"JAMA Oncol"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"188314","DOI":"10.1016\/j.bbcan.2019.188314","article-title":"Challenges in liver cancer and possible treatment approaches.","volume":"1873","author":"Anwanwan","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"914192","DOI":"10.3389\/fonc.2022.914192","article-title":"A practical nomogram and risk stratification system predicting the cancer-specific survival for patients with advanced hepatocellular carcinoma.","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"1658403","DOI":"10.1155\/2021\/1658403","article-title":"Development and evaluation of nomograms to predict the cancer-specific mortality and overall mortality of patients with hepatocellular carcinoma.","volume":"2021","author":"Ni","year":"2021","journal-title":"Biomed Res Int"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"789026","DOI":"10.3389\/fpubh.2021.789026","article-title":"A web-based prediction model for cancer-specific survival of elderly patients with early hepatocellular carcinoma: a study based on SEER database.","volume":"9","author":"He","year":"2022","journal-title":"Front Public Health"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2018.10.008","article-title":"Hepatocellular carcinoma in the setting of alcohol-related liver disease.","volume":"70","author":"Ganne-Carrie","year":"2019","journal-title":"J Hepatol"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","article-title":"Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.","volume":"392","author":"Griswold","year":"2018","journal-title":"Lancet"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.drudis.2021.02.001","article-title":"Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma.","volume":"26","author":"Zhang","year":"2021","journal-title":"Drug Discov Today"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma.","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jhep.2019.02.023","article-title":"Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma.","volume":"70","author":"Xu","year":"2019","journal-title":"J Hepatol"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13027-022-00468-6","article-title":"Early and late recurrence after hepatectomy in patients with low-level HBV-DNA hepatocellular carcinoma under antiviral therapy.","volume":"17","author":"Li","year":"2022","journal-title":"Infect Agent Cancer"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcma.2017.06.018","article-title":"Impact of tumor size on the prognosis of hepatocellular carcinoma in patients who underwent liver resection.","volume":"81","author":"Dai","year":"2018","journal-title":"J Chin Med Assoc"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s00432-020-03331-6","article-title":"Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma.","volume":"146","author":"Zheng","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"650","DOI":"10.21037\/jgo.2017.06.07","article-title":"The role of neoadjuvant radiotherapy for locally-advanced rectal cancer with resectable synchronous metastasis.","volume":"8","author":"Fossum","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.21.01963","article-title":"Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1).","volume":"40","author":"Lyu","year":"2022","journal-title":"J Clin Oncol"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s005350300038","article-title":"Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan integrated staging score (JIS score).","volume":"38","author":"Kudo","year":"2003","journal-title":"J Gastroenterol"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1159\/000509424","article-title":"Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition).","volume":"9","author":"Zhou","year":"2020","journal-title":"Liver Cancer"},{"key":"R37-20250503","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1097\/SLA.0b013e31827da749","article-title":"Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis.","volume":"258","author":"Nathan","year":"2013","journal-title":"Ann Surg"},{"key":"R38-20250503","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5582\/bst.2021.01091","article-title":"Conversion therapy and maintenance therapy for primary hepatocellular carcinoma.","volume":"15","author":"Zhou","year":"2021","journal-title":"Biosci Trends"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:44:08Z","timestamp":1746319448000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":38,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039480","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,9,20]]}}}